Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class

Journal of Immunotherapy

Volumn 30, Issue 8, 2007, Pages 798-807

  Brischwein, Klaus ^a   Parr, Larissa ^a   Pflanz, Stefan ^a   Volkland, Jörg ^a   Lumsden, John ^a   Klinger, Matthias ^a   Locher, Mathias ^a   Hammond, Scott A ^b   Kiener, Peter ^b   Kufer, Peter ^a   Schlereth, Bernd ^a   Baeuerle, Patrick A ^a,c  

^a MICROMET AG   (Germany)

^b MEDIMMUNE   (United States)

^c Micromet Inc   (United States)

Author keywords

BispecifIc antibody; CD19; CD3; Cytokine release; EpCAM; MT103; MT110; Redirected lysis; T cell activation

Indexed keywords

BISPECIFIC ANTIBODY; BITE MOLECULE; CD69 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; MT 103; MT 110; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY ENGINEERING; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CELL THERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE ACTIVATION; TARGET CELL; UPREGULATION;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, CD3; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; CYTOKINES; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MACACA FASCICULARIS; MICE; MUROMONAB-CD3; RECOMBINANT PROTEINS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 37349123501     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318156750c     Document Type: Article

References (33)

1. Weiner GJ, De Gast GC. Bispecific monoclonal antibody therapy of B-cell malignancy. Leuk Lymphoma. 1995;16:199-207.
2. Segal DM, Qian JH, Mezzanzanica D, et al. Targeting of anti-tumor responses with bispecific antibodies. Immunobiology. 1992;185:390-402.
3. Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature. 1985;314:628-631.
4. Munn DH. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol. 2006;18:220-225.
5. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005;8:369-380.
6. Kageshita T, Hirai S, Ono T, et al. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol. 1999;154:745-754.
7. Cabrera T, Maleno I, Lopez-Nevot MA, et al. High frequency of HLA-B44 allelic losses in human solid tumors. Hum Immunol. 2003;64:941-950.
8. Hicklin DJ, Wang Z, Arienti F, et al. beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest. 1998;101:2720-2729.
9. Kufer P, Lutterbuse R, Baeuerle PA. A revival of bispecific antibodies. Trends Biotechnol. 2004;22:238-244.
10. Wolf E, Hofmeister R, Kufer P, et al. BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today. 2005;10:1237-1244.
11. Offner S, Hofmeister R, Romaniuk A, et al. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol. 2006;43:763-771.
12. Hoffmann P, Hofmeister R, Brischwein K, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer. 2005;115:98-104.
13. Brischwein K, Schlereth B, Guller B, et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol. 2006;43:1129-1143.
14. Schlereth B, Fichtner I, Lorenczewski G, et al. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res. 2005;65:2882-2889.
15. Dreier T, Baeuerle PA, Fichtner I, et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol. 2003;170:4397-4402.
16. Bargou RC, Kufer P, Kirchinger P, et al. MT103 (MEDI-538) induces B cell depletion, clearance of bone marrow infiltration and clinical responses in heavily pre-treated NHL patients: first data from dose-escalation study MT103-104. Haematologia. 2006;91(S1):71.
17. Schlereth B, Quadt C, Dreier T, et al. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother. 2006;55:503-514.
18. Dreier T, Lorenczewski G, Brandl C, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer. 2002;100:690-697.
19. Hammond SA, Lutterbuese R, Roff S, et al. Selective targeting and potent control of tumor growth by an EphA2/CD3 bispecific single-chain antibody construct. Cancer Res. 2007;67:3927-3935.
20. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer. 2007;96:417-423.
21. Brandl C, Haas C, d'Argouges S, et al. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol Immunother. In press.
22. Chatenoud L. OKT3-induced cytokine-release syndrome: prevention effect of anti-tumor necrosis factor monoclonal antibody. Transplant Proc. 1993;25:47-51.
23. Norman DJ, Chatenoud L, Cohen D, et al. Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies. Transplant Proc. 1993;25:89-92.
24. Schneider CK, Kalinke U, Lower J. TGN1412 - a regulator's perspective. Nat Biotechnol. 2006;24:493-496.
25. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018-1028.
26. Kipriyanov SM, Moldenhauer G, Schuhmacher J, et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol. 1999;293:41-56.
27. Bohlen H, Manzke O, Patel B, et al. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res. 1993;53:4310-4314.
28. Kiewe P, Hasmuller S, Kahlert S, et al. Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res. 2006;12:3085-3091.
29. De Gast GC, Van Houten AA, Haagen IA, et al. Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies. J Hematother. 1995;4:433-437.
30. Kroesen BJ, Nieken J, Sleijfer DT, et al. Approaches to lung cancer treatment using the CD3 x EGP-2-directed bispecific monoclonal antibody BIS-1. Cancer Immunol Immunother. 1997;45:203-206.
31. Bortoletto N, Scotet E, Myamoto Y, et al. Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells. Eur J Immunol. 2002;32:3102-3107.
32. Boesteanu A, Brehm M, Mylin LM, et al. A molecular basis for how a single TCR interfaces multiple ligands. J Immunol. 1998;161:4719-4727.
33. al-Ramadi BK, Jelonek MT, Boyd LF, et al. Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR. J Immunol. 1995;155:662-673.